Radspherin[®] shows favorable safety profile in the first interim safety readout from the ongoing randomized phase 2 trial in ovarian cancer
· Radspherin[®] continues to show a favorable safety and tolerability profile · No serious adverse event in the trial was assessed as possibly related to Radspherin[®] · Independent Data Monitoring Committee recommended continuing the trial without modification · Interim efficacy readout on track for April 2027
Oncoinvent presents 3Q company update in live webcast
Oslo, Norway, 28 October 2026 – Oncoinvent ASA (ONCIN), … Read more
Oslo, Norway, 28 October 2026: Oncoinvent has granted t … Read more
Oncoinvent appoints Dr Zuzana Jiráková Trnková as Chief Medical Officer to lead Phase 3 preparations for Radspherin[®]
· Dr Jiráková Trnková brings more than 20 years of clinical development experience from Bayer, BioNTech, and Highlight Therapeutics, with expertise spanning global pivotal Phase 3 trials and alpha-emitting radiopharmaceuticals
Invitation to business update – Wednesday 28 October 2026
Oslo, Norway, 20 October 2026 – Oncoinvent ASA (ONCIN), … Read more
Oncoinvent ASA – Cancellation of subsequent repair offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY … Read more
Oncoinvent ASA – Disclosure of large shareholding
Oslo, 2 October 2026: Reference is made to the stock ex … Read more
Oncoinvent ASA – Mandatory notification of trade – Return of lent shares following Private Placement
Oslo, 30 September 2026: Reference is made to the stock … Read more
Oncoinvent ASA – New share capital registered
Reference is made to the stock exchange announcement ma … Read more
Oncoinvent to present three abstracts at EANM and ESMO 2026
Oslo, Norway – 30 September 2026 – Oncoinvent, a clinic … Read more